Stock Scorecard
Stock Summary for Cellectis (CLLS) - $2.60 as of 8/29/2025 3:13:10 PM EST
Total Score
9 out of 30
Safety Score
8 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for CLLS
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CLLS
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CLLS
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for CLLS
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for CLLS (8 out of 100)
| Stock Price Rating (Max of 10) | 3 |
| Historical Stock Price Rating (Max of 10) | 4 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 2 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 2 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 2 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | -10 |
Latest News for for CLLS
Financial Details for CLLS
Company Overview |
|
|---|---|
| Ticker | CLLS |
| Company Name | Cellectis |
| Country | USA |
| Description | Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors to attack and eradicate cancer cells. The company is headquartered in Paris, France. |
| Sector Name | LIFE SCIENCES |
| Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | 11/10/2025 |
Stock Price History |
|
| Last Day Price | 2.60 |
| Price 4 Years Ago | 8.12 |
| Last Day Price Updated | 8/29/2025 3:13:10 PM EST |
| Last Day Volume | 35,096 |
| Average Daily Volume | 214,585 |
| 52-Week High | 3.24 |
| 52-Week Low | 1.10 |
| Last Price to 52 Week Low | 136.36% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 36.18 |
| Sector PE | 60.89 |
| 5-Year Average PE | -2.21 |
| Free Cash Flow Ratio | 3.13 |
| Industry Free Cash Flow Ratio | 20.54 |
| Sector Free Cash Flow Ratio | 30.76 |
| Current Ratio Most Recent Quarter | 1.38 |
| Total Cash Per Share | 0.83 |
| Book Value Per Share Most Recent Quarter | 1.34 |
| Price to Book Ratio | 2.69 |
| Industry Price to Book Ratio | 7.19 |
| Sector Price to Book Ratio | 26.74 |
| Price to Sales Ratio Twelve Trailing Months | 4.26 |
| Industry Price to Sales Ratio Twelve Trailing Months | 52.00 |
| Sector Price to Sales Ratio Twelve Trailing Months | 13.32 |
| Analyst Buy Ratings | 1 |
| Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
| Total Shares Outstanding | 72,325,000 |
| Market Capitalization | 188,045,000 |
| Institutional Ownership | 18.89% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 63.62% |
| Reported EPS 12 Trailing Months | -0.59 |
| Reported EPS Past Year | -0.39 |
| Reported EPS Prior Year | -1.37 |
| Net Income Twelve Trailing Months | -59,297,000 |
| Net Income Past Year | -36,761,000 |
| Net Income Prior Year | -101,059,000 |
| Quarterly Revenue Growth YOY | 91.40% |
| 5-Year Revenue Growth | 22.27% |
| Operating Margin Twelve Trailing Months | -52.70% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 59,809,000 |
| Total Cash Past Year | 143,251,000 |
| Total Cash Prior Year | 136,708,000 |
| Net Cash Position Most Recent Quarter | 10,246,000 |
| Net Cash Position Past Year | 99,261,000 |
| Long Term Debt Past Year | 43,990,000 |
| Long Term Debt Prior Year | 28,444,000 |
| Total Debt Most Recent Quarter | 49,563,000 |
| Equity to Debt Ratio Past Year | 0.75 |
| Equity to Debt Ratio Most Recent Quarter | 0.66 |
| Total Stockholder Equity Past Year | 131,033,000 |
| Total Stockholder Equity Prior Year | 84,695,000 |
| Total Stockholder Equity Most Recent Quarter | 97,111,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -36,596,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.51 |
| Free Cash Flow Past Year | 19,146,000 |
| Free Cash Flow Prior Year | -25,819,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | None |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.10 |
| MACD Signal | 0.17 |
| 20-Day Bollinger Lower Band | 0.75 |
| 20-Day Bollinger Middle Band | 1.88 |
| 20-Day Bollinger Upper Band | 3.02 |
| Beta | 3.06 |
| RSI | 48.68 |
| 50-Day SMA | 1.77 |
| 150-Day SMA | 2.15 |
| 200-Day SMA | 2.86 |
System |
|
| Modified | 8/29/2025 8:26:41 PM EST |